← Back to patent-cliff list
MBF-015
Tier C — Watch / tradeMBF-015
Medibiofarma SL
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HDAC2, HDAC1
Indications (approved)：亨廷顿舞蹈症
Regional status
US
-
EU
Phase II
2024-02-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MBF-015?
Approved indications include: 亨廷顿舞蹈症.
When does the MBF-015 patent expire?
No public expiry year is available for MBF-015 yet; this page updates once verified.
How do I get a quote for MBF-015 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02